Type 2 DiabetesGLIMMERNCT07272837
Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass
An observational study of Type 2 Diabetes and Obesity, run by University of Alberta at 1 site in Canada.
Trial summary
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Type 2 Diabetes, Obesity, Semaglutide
- How many people
- 50 participants
- Where
- 1 siteCanada
- Study dates
- 15 May 2026to 30 Apr 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Individuals who are starting semaglutide and are able to attend study visits at the Mazankowski Alberta Heart Institute.
Who may be able to join
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Who cannot join
- Current use of semaglutide for more than 2 weeks
- Major recent heart issues or other severe health conditions
- Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
- Dependence on a mobility aid (unable to participate in exercise MRI)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Mazankowski Alberta Heart Institute
Edmonton, Alberta, T6G 0M9
Krista Jong, 780-492-9010, glimmer@ualberta.ca
About this study
Official title: GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.
This study involves (3) in-person study visits. At each visit, participants will be asked to:
- Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
- Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
- Complete questionnaires related to demographics, health information, physical activity, and nutrition.
- Have a blood sample collected from a vein in your arm.
- Have your blood levels assessed through three finger pricks.
- Complete three days of food records.
- Conditions
- Type 2 Diabetes, Obesity, Semaglutide, GLP-1, Diabetes
- Keywords
- Semaglutide, Type 2 Diabetes, Diabetes, Obesity, Body Composition, Muscle Mass, Skeletal Muscle Mass, Cardiac Muscle Mass, GLP-1 Receptor Agonist, GLP-1, MRI, Magnetic Resonance Imaging
- Medical subject headings
- Diabetes Mellitus, Type 2, Obesity, Diabetes Mellitus
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in skeletal and cardiac muscle mass
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Dec 2025
- Study start15 May 2026
- Primary completion31 Dec 2027 (estimated)
- Study completion30 Apr 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- More trials run by University of AlbertaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Alberta
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07272837
- Sponsor's protocol ID
- Pro00153724
- Acronym
- GLIMMER
- Status last verified
- Jul 2026
- First submitted
- 26 Nov 2025
- Last updated
- 17 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- GLP-1 Receptor Agonist-Induced Muscle Mass Evaluation and Retention
- ClinicalTrials.gov ID
- NCT07272837
- Acronym / sponsor ID
- GLIMMER / Pro00153724
- Conditions
- Type 2 Diabetes, Obesity, Semaglutide, GLP-1, Diabetes
- Keywords
- Semaglutide, Type 2 Diabetes, Diabetes, Obesity, Body Composition, Muscle Mass, Skeletal Muscle Mass, Cardiac Muscle Mass
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- University of AlbertaUniversity, hospital or other
- Study start
- 15 May 2026 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 30 Apr 2028 (estimated)
- First posted
- 9 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.
This study involves (3) in-person study visits. At each visit, participants will be asked to:
- Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
- Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
- Complete questionnaires related to demographics, health information, physical activity, and nutrition.
- Have a blood sample collected from a vein in your arm.
- Have your blood levels assessed through three finger pricks.
- Complete three days of food records.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Individuals who are starting semaglutide and are able to attend study visits at the Mazankowski Alberta Heart Institute.
Key inclusion criteria (3 listed)
- Adults 18-80 years of age
- Starting semaglutide for type 2 diabetes or weight loss
- Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)
Key exclusion criteria (4 listed)
- Current use of semaglutide for more than 2 weeks
- Major recent heart issues or other severe health conditions
- Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
- Dependence on a mobility aid (unable to participate in exercise MRI)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Changes in skeletal and cardiac muscle mass
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Jul 2026.
- Study information and pre-screening surveyLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Type 2 Diabetes and Obesity, run by University of Alberta at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Krista Jong, RD, BSc (780-492-9010, glimmer@ualberta.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in skeletal and cardiac muscle mass (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2026; AzTrials last refreshed its copy on 8 Nov 2026.